TORONTO and HOUSTON, Oct. 16, 2018 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immunotherapy company, developing first-in-class Superkines and Empowered Cytokines, today announced that it will be presenting results related to the ongoing MDNA55 Phase 2b clinical trial for the treatment of recurrent glioblastoma at the European Society for Medical Oncology (ESMO) Congress to be held from October 19 to 23, 2019 in Munich Germany.
The details of the poster discussion and display are as follows:
MDNA55 Poster Discussion:
Dr. Martin F. Bexon, MBBS
Understanding Biological Activity, Tumor Response and Pseudoprogression in a Phase-2b Study of MDNA55 in Adults with Recurrent or Progressive Glioblastoma
Saturday October 20, 2018 at 17:10
Hall B3, Room 23
Dr. Frank Winkler (University of Heidelberg and the German Cancer Research Center, Heidelberg, Germany)
MDNA55 Poster Display information:
Starting at 9:00am Saturday, 20 October, 2018 (poster will be displayed for the duration of the whole Congress)
A press release outlining the clinical results presented will be issued following the presentation and a copy of the poster will be available on our website at www.medicenna.com
In addition, Dr. Fahar Merchant, Chairman, President and CEO and Elizabeth Williams, CFO of Medicenna will be attending the BIO Investor Forum to be held October 17 & 18, 2018 in San Francisco.
Medicenna is a clinical stage immunotherapy company focused on oncology and the development and commercialization of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines™ and first in class Empowered Cytokines™ (ECs) for the treatment of a broad range of cancers. Medicenna's wholly owned subsidiary, Houston-based Medicenna BioPharma, is specifically targeting the Interleukin-4 Receptor (IL4R), which is over-expressed by at least 20 different types of cancer affecting more than one million new cancer patients every year. Supported by a significant non-dilutive grant from CPRIT (Cancer Prevention and Research Institute of Texas), Medicenna's lead IL4-EC, MDNA55 is enrolling patients in a Phase 2b clinical trial for recurrent glioblastoma (rGBM), the most common and uniformly fatal form of brain cancer, at top-ranked brain cancer centres in the US. MDNA55 has completed three clinical trials in 72 patients, including 66 adults with rGBM, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA respectively. For more information, please visit www.medicenna.com.
SOURCE Medicenna Therapeutics Corp.